Epi­der­mol­y­sis bul­losa: FDA seeks to help de­vel­op­ment of new treat­ments

The FDA re­cent­ly re­leased guid­ance to help com­pa­nies de­vel­op new treat­ments for epi­der­mol­y­sis bul­losa (EB), which is a de­bil­i­tat­ing and of­ten fa­tal rare dis­ease. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.